Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.85 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.85 |
| ▸ | USP2 | O75604 | 5/20 | 0.85 |
| ▸ | PGR | P06401 | 5/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.85 |
| ▸ | AR | P10275 | 2/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.85 |
| ▸ | CNR1 | P21554 | 1/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beclomethasone 17-Monopropionate SCHEMBL24581289 | 1.00 | CYP3A4 (0.85) | CYP3A4NR3C1USP2PGRHIF1A | |
| Beclomethasone 17-Monopropionate SCHEMBL10354250 | 1.00 | CYP3A4 (0.85) | CYP3A4NR3C1USP2PGRHIF1A | |
| Beclomethasone 17-Monopropionate SCHEMBL10354253 | 1.00 | CYP3A4 (0.85) | CYP3A4NR3C1USP2PGRHIF1A | |
| Beclomethasone 17-Monopropionate SCHEMBL10354251 | 1.00 | CYP3A4 (0.85) | CYP3A4NR3C1USP2PGRHIF1A | |
| SCHEMBL6860007 | 0.94 | CYP3A4 (0.76) | CYP3A4NR3C1USP2PGRHIF1A | |
| SCHEMBL11047292 | 0.93 | CYP3A4 (0.85) | CYP3A4NR3C1USP2PGRHIF1A | |
| SCHEMBL11047288 | 0.93 | CYP3A4 (0.85) | CYP3A4NR3C1USP2PGRHIF1A | |
| SCHEMBL11047296 | 0.93 | CYP3A4 (0.85) | CYP3A4NR3C1USP2PGRHIF1A | |
| SCHEMBL10354657 | 0.93 | NR3C1 (0.80) | CYP3A4NR3C1USP2PGRHIF1A | |
| SCHEMBL10354655 | 0.93 | NR3C1 (0.80) | CYP3A4NR3C1USP2PGRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744657-A1 | THERAPEUTIC AGENT FOR HUMAN GRAFT VERSUS HOST DISEASE AND COMBINATION THEREOF | National University Corporation Okayama University (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-4567037-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| CN-120114423-A | Beclomethasone dipropionate suspension for inhalation and preparation method thereof | 苏州弘森药业股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119555851-B | Method for measuring in-vitro dissolution curve of suspension for inhalation | 上海新黄河制药有限公司 | 2025-06-03 | — | — | CN | claimed |
| US-20250170069-A1 | NANOPREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD AND USE THEREOF | XIANGYA HOSPITAL CENTRAL SOUTH UNIV (CN) | 2025-05-29 | — | — | US | claimed |
| CN-114702594-B | Dual specificity antibodies | 豪夫迈·罗氏有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119355175-B | Method for non-targeted detection of 86 hormone interferents in aquatic ecosystem, hormone interferent ecological risk evaluation method and optimal control sequencing method | 成都市食品检验研究院 | 2025-04-29 | — | — | CN | claimed |
| EP-4541275-A1 | ANALYTE SENSOR, AND PREPARATION METHOD THEREFOR AND APPLICATION METHOD THEREOF | Shanghai United Imaging Microelectronics Technology Co., Ltd. (CN) | 2025-04-23 | — | — | EP | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| US-20250109171-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2025-04-03 | — | — | US | claimed |
| EP-1097712-A1 | STEROID-CONTAINING CATAPLASMS AND PROCESS FOR PRODUCING THE SAME | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-05-09 | — | — | EP | claimed |
| US-6197326-B1 | ADMINISTERING HYALURONIC ACID, CHONDROITIN SULFATE AND SALTS BY INJECTION FOR JOINT PAIN | SSP CO., LTD. (JP) | 2001-03-06 | — | — | US | claimed |
| US-5897878-A | ORALLY ADMINISTERING DELIVERY SYSTEM IN WHICH FLUID IMBIBITION CAUSES HYDROPHILIC POLYMER TO AGGREGATE IN SITU IN PRESENCE OF POLYHYDROXY COMPOUND AND CAUSES PUSH LAYER TO ABSORB FLUID AND DELIVER AGGREGATES CONTAINING STEROID | ALZA CORPORATION (US) | 1999-04-27 | — | — | US | claimed |
| US-5650170-A | Dosage form for delivering drug at a controlled rate to the intestine and to the colon | ALZA CORPORATION (US) | 1997-07-22 | — | — | US | claimed |
| EP-0521074-B1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORP (US) | 1994-03-02 | — | — | EP | claimed |
| US-5178866-A | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORPORATION (US) | 1993-01-12 | — | — | US | claimed |
| EP-0521074-A1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE. | ALZA CORP (US) | 1993-01-07 | — | — | EP | claimed |
| WO-1991014426-A1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORPORATION (US) | 1991-10-03 | — | — | WO | claimed |
| US-4879274-A | IMPROVED ABSORPTION | KAO CORPORATION (JP) | 1989-11-07 | — | — | US | claimed |
| US-4765983-A | INTESTINAL-SOLUBLE POLYMER AND MEDICAMENT | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-08-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109171-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | REN, VHL, RCC2 | CYP3A4 4216/4885NR3C1 3381/4885USP2 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.